Clinical trials: Neoplasms, Pharyngeal
Nasopharyngeal Carcinoma, Nutritional Support
Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma
Concurrent chemoradiotherapy(CCRT) is the principal treatment for nasopharyngeal carcinoma(NPC). Studies have shown that malnutrition is very common in patients with NPC after chemoradiotherapy.
- Trial name
- NCT04823468
- Testing
- Abbott®Ensure, Intensity Modulated Radiation Therapy, cisplatin
- Where
- 13 sites in China
- Volunteers
- 236 people
- Sponsor
- Jinsheng Hong
Nasopharyngeal Neoplasms
Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma
This is an open-label, parallel controlled, phase IIa exploratory study that evaluates the efficacy and safety of Toripalimab (PD-1 Antibody) combined with induction chemotherapy （Albumin-bound paclitaxel and cisplatin ）and…
- Trial name
- NCT04446663
- Testing
- Toripalimab, Albumin-bound Paclitaxel, Cisplatin
- Volunteers
- 50 people
- Sponsor
- First People's Hospital of Foshan
Head and Neck Cancer, Oropharynx Cancer
Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer
Clinician directed prophylactic swallowing therapy will improve immediate (four weeks +/- two weeks) and short-term (26 weeks +/- four weeks) post-treatment swallowing function and quality of life versus patient directed home…
- Trial name
- NCT03435471
- Testing
- Prophylactic Swallowing Home Exercise Program, Clinician-Directed Prophylactic Swallowing Exercises
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Miami
Nasopharyngeal Carcinoma (NPC)
Biomarker Analysis Data From a Randomized Phase II Study in Patients With Nasopharyngeal Carcinoma Treated With Chemotherapy and Radiotherapy
Clinicopathological and genomic data (Next generation sequencing and IHC/CISH) in available tissues were performed in patients with nasopharyngeal carcinoma who participated in a previously conducted randomized phase II study…
- Trial name
- NCT07741110
- Testing
- Next generation sequencing, Immunohistochemistry/CISH
- Volunteers
- 141 people
- Sponsor
- Hellenic Cooperative Oncology Group
Laryngeal Cancer, Hypopharyngeal Cancer
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
The purpose of this study is to investigate the relationship between SDF-1/CXCR4 and metastasis of laryngeal and hypopharyngeal squamous cell carcinomas.
- Conditions
- Laryngeal Cancer, Hypopharyngeal Cancer, Metastasis
- Trial name
- NCT00174096
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Recurrent Nasopharyngeal Carcinoma
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy
- Trial name
- NCT06235203
- Testing
- endoscopic surgery, Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy
- Where
- 7 sites in China
- Volunteers
- 154 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma
Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy
Background:Although concurrent chemoradiotherapy is effective for improving disease-free survival and overall survival in patients with locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT03045484
- Testing
- Controlled-release oxycodone, Chemoradiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Head and Neck Cancer, Hearing Loss
Maximizing Quality of Life After Cancer Through Rehabilitation
Treatment for head and neck cancer (HNC) often includes cisplatin chemotherapy and radiation. This treatment causes hearing loss and trouble swallowing in 70% of patients.
- Conditions
- Head and Neck Cancer, Hearing Loss, Tinnitus, Dysphagia
- Trial name
- TIMELY REHAB (NCT07622407)
- Testing
- TIMELY REHAB
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- VA Office of Research and Development
Nasopharyngeal Cancer
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.
- Trial name
- NCT00304694
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Recurrent / Metastatic Nasopharyngeal Cancer
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
This study is a single-arm, randomized, open-label, multi-cohort Phase Ib clinical trial. The experimental drug is TQB2858 Injection. The trial was divided into 3 cohorts.
- Trial name
- NCT05198531
- Testing
- TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection
- Where
- 7 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Oropharynx Cancer
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
This prospective study aims to utilize pre- and mid-treatment PET-CT to guide de-escalation of radiation therapy in HPV-related squamous cell carcinoma of the oropharynx.
- Trial name
- NCT03416153
- Testing
- Carboplatin, Radiation Therapy, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 91 people
- Sponsor
- University of Michigan Rogel Cancer Center
Nasopharyngeal Neoplasms
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients
A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma…
- Trial name
- NCT02505139
- Testing
- the number of circulating tumor cells
- Volunteers
- 166 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, Cancer
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced
- Trial name
- NCT03383094
- Testing
- Pembrolizumab, Radiation therapy, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 126 people
- Sponsor
- Loren Mell, MD
Head and Neck Cancer, Oral Cavity Cancer
Immune Biomarker Study for Head and Neck Cancer
The aim of this prospective non-interventional multi-center trial is to study the prognostic value of intratumoral and systemic immune biomarkers in newly diagnosed non-metastatic head and neck cancer.
- Conditions
- Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer, Hypopharyngeal Cancer
- Trial name
- ImmunBio-KHT (NCT05375266)
- Testing
- Sampling
- Where
- 3 sites in Germany
- Volunteers
- 1,100 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Drug Use for Unapproved Schedule
EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug
PCR-DNA of EBV test is a good prognostic indicator for survival after treatment (report: Prognostic Impact of Plasma, Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation…
- Trial name
- NCT03656965
- Testing
- Acyclovir 800 MG, Radiotherapy and chemotherapy
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Glottic Carcinoma, Supraglottic Carcinoma
Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)
For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery, open partial laryngectomy, radiotherapy, and transoral robotic surgery were performed according to NCCN guidelines…
- Conditions
- Glottic Carcinoma, Supraglottic Carcinoma, Subglottic Carcinoma, Pyriform Sinus Carcinoma
- Trial name
- NCT04908696
- Testing
- routines
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma
EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients
EUS-FNA for RPLN in NPC
- Trial name
- NCT03006588
- Testing
- EUS-FNA for RPLN in NPC patients
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Study of DC-CIK to Treat NPC
Concurrent of radiotherapy and chemotherapy is the main treatment method for patients with nasopharyngeal carcinoma (NPC). However, Relapse remains the major cause of treatment failure.
- Trial name
- NCT01821495
- Testing
- DC-CIK, Dendritic and Cytokine-induced Killer Cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangxi Medical University
Head and Neck Cancer
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00003327
- Testing
- paclitaxel
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theradex